Beta-Thalassemia Completed Phase 3 Trials for Luspatercept (DB12281)

Also known as: Β -Thalassemia / Β Thalassemia / Thalassemia, Beta / B-Thalassemia / Β-thalassemia / Thalassaemia beta / Beta Thalassaemia / Beta Thalassemia / B Thalassemia / Thalassemia beta / Beta thalassemia (disorder) / Beta-thalassaemia / Thalassaemia intermedia / Thalassemia intermedia (disorder) / Thalassemia intermedia / Mediterranean anemia / Mediterranean anaemia / Thalassemia major / Cooley's anaemia / Thalassaemia major / Thalassemia major (disorder) / Homozygous beta thalassemia (disorder) / Cooley's anemia

IndicationStatusPhase
DBCOND0027982 (Beta-Thalassemia)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02604433An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) ThalassemiaTreatment